Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Recordati Industria Chimica e Farmaceutica SPA ( (IT:REC) ) just unveiled an announcement.
Recordati has reported strong financial performance in the first quarter of 2025, with consolidated net revenues increasing by 11.9% to €680.0 million. The company’s growth is driven by robust performance in its Specialty & Primary Care and Rare Diseases segments, with significant contributions from the extension of Isturisa’s indication and the approval of Signifor LAR in China. The company maintains its financial targets for 2025 and anticipates continued momentum through 2027, supported by strategic growth initiatives and disciplined cost management.
More about Recordati Industria Chimica e Farmaceutica SPA
Recordati Industria Chimica e Farmaceutica S.p.A. operates in the pharmaceutical industry, focusing on Specialty & Primary Care and Rare Diseases. The company is known for its development and distribution of pharmaceuticals, with a market focus on both common and rare conditions.
Average Trading Volume: 471,350
Technical Sentiment Signal: Buy
Current Market Cap: €10.98B
See more insights into REC stock on TipRanks’ Stock Analysis page.